Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Decline in Short Interest

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 500 shares, a decline of 93.8% from the November 30th total of 8,100 shares. Based on an average daily trading volume, of 24,400 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company’s shares are sold short.

Xenetic Biosciences Trading Down 2.7 %

Shares of NASDAQ XBIO opened at $4.04 on Friday. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20. The business has a 50-day moving average price of $4.02 and a two-hundred day moving average price of $3.98. The firm has a market capitalization of $6.23 million, a PE ratio of -1.52 and a beta of 2.24.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. Research analysts anticipate that Xenetic Biosciences will post -1.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.